Quantcast Archives 0307.html
Search by tag or site Login to my blog ? Start my own blog














TheMoneyBlogs
Home
About
Create your own blog
Contact us
Vote for this blog!

BioHealth Investor

BioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network.

March 2007

Biotech Daily Review: Novartis Pulls Zelnorm Off The Market
Federal Circuit Allows Declaratory Judgment Jurisdiction For Generic Drug Patent Challenges
Will Dendreon's Cancer Vaccine Win Final Fda Approval?
Alexion Takes Rising Healthcare Costs To Next Level!
Dendreon: Massive Pre-market Action
Dendreon Conference Call Transcript Summary & Commentary
Merck Prevails In Patent Term Extension Case At Federal Circuit
Art Is Not A Luxury!
Dendreon's Big Day: Favorable Fda Review, Wild Trading Day Tomorrow
Biotech Daily Review: Curagen Gets $155m For Gene Sequence Division
Something More To Targeted Genetics?
Beijing Med-pharm Extends Chinese Distribution Network
Biotech Daily Review: Sanofi-aventis Lands Cancer Vaccine For $680m
Dendreon's Last Day Ahead Of Fda
Exegenics: Dr.frost Continues His Hot Hand
Weekly Top Biotech And Medical Business Articles
Strategy For Investing In Small Biotechs
Dendreon: A Make Or Break Week
Biotech Weekly Review: Biotech Recovers Some Lost Ground
Dendreon: Trading Strategy Ahead Of Fda Review
Mylan Launches Generic Norvasc; Pfizer Counters With Own Generic
Biotech Daily Review: A Perfect Storm For Genentech And Amgen
Court Invalidates Pfizer's Norvasc Patent; Mylan's Generic To Launch Soon
Bad News From Amgen And Genentech
Dendreon Interest Remains; Early Volume Surges
Can Amgen Get The Gorilla Off Its Neck?
Novadel Should End Relationship With Hana
Xshares Will Offer Asian Biotech Etf
Novo Nordisk: Cramer's Defensive Diabetes Play
Biotech Daily Review: Biosimilar Drug Enters Trial
Flu Vaccine Surplus Highlights Lack Of Communication
Nursing Home Stocks Could Rise As Alzheimer's Increases
Toll-like Receptors: Coley, Idera, And Dynavax Lead The Way
Biotech Daily Review: Atherogenics Tumbles On Drug Test Failure
Atherogenics Implodes As Heart Disease Study Fails
Biotech Weekly Review: Biotech Slides Slightly Lower
High Cost Of New Cancer Drugs Force Government Intervention
Biotech: March Madness May Continue Untill Summer
Protecting Ip & Regulatory Compliance During Development Collaborations
California Awards $74.5 Million For Stem Cell Research
Hollis Eden: What Else They Have Under The Hood
Biotech Daily Review: Adams Respiratory Guides Lower
Tongjitang Chinese Medicines Prices At $10
Cancer Drug But Not Drug Company Praised By Networks
Thermogenesis: Volume, Stock Jump In Late Trading
Biotech Daily Review: Critical Therapeutics Climbs On Co-promotion Deal
Our Knowledge Of Cancer Remains Incomplete
State Prescription Drug Legislature Review
Biotech Daily Review: Glaxo Gets Approval For Tykerb
Johnson & Johnson And Amgen: The Drug Marketing Blues
Boston Scientific Looks To Ipo Unit As Concerns About Main Business Linger
Pharmion: Investors Must Look Beyond 2007
A Note On Fda Approvable Letters
Cramer Calls Hansen Medical The Next Intuitive Surgical
Biotech Daily Review: Schering-plough Buys Organon For $14.4 B
Altus Pharmaceuticals: Great Growth At Good Value
Healthshares Launches 9 New Etfs
New Class Of Drug-Eluted Stents On The Horizon
Biotech Weekly Review: Flat Week, No Complaints
Biotech Daily Review: Amgen Must Post Black Box Warning
Aradigm: A Speculative Value Play
Biotech Daily Review: Hollis-eden Loses Stockpile Contract For Neumune
Audioconference: "strategies To Defend Against Generic Drug Patent Challenges"
Fda Congressional Testimony On Importation
Hollis-eden: May Reorganize Following Contract Cancellation
Bruker Biosciences: Earnings Growing, Insiders Buying
Biotech Daily Review: Avalon Signs $200 Million Deal With Merck
Live Interview: Myogen Founder Dr.bristow
Cardiome, Amylin: Great Biotech Values In Market Downturn
Biotech Daily Review: Novartis Gets Approval For Hypertensive Drug
Senate Committee On Health To Hold Hearing On Follow-on Biologics
Fda Failing To Acknowledge Image Problems
Tuesday's Top Biotech & Medical Stocks
Fda Cuts Women Health Budgeting
Biotech Daily Review: Lilly Buys Insomnia-focused Hypnion
Vertex Vs. Schering-plough: Hepatitis C Protease Inhibitors
Apotex Ceo Ordered To Pay $3.1 Million To Eon Labs
Monday's Top Biotech & Medical Stocks
Biotech Weekly Review: Rough Week, Ipos Bright Spot
Hollis-Eden: Stock Volatility To Precede Contract Announcement
Thermogenesis Ups Production Of Cord Blood Stem Cell Processing Bags
Biotech Daily Review: Hopeful Results From Hiv Conference
Biotech And Medical Venture Deals Roundup
Ibd Weekly Top Ranked Medical Stocks
This Week's Top Biotech And Medical Business Articles
Friday's Top Biotech & Medical Stocks
Best & Worst Healthcare And Biotech Mutual Funds
Thursday's Top Biotech & Medical Stocks
Tiny Biosante Could Skyrocket With Estrogen Replacement Gel
Pfizer Successfully Defends Its Norvasc Patent Again, This Time Against Mylan
New Fda Commisioner Silent Since Taking Helm
Astellas And Boehringer Ingelheim Defeat Ranbaxy In Flomax Case
Wednesday's Top Biotech & Medical Stocks

<< Home

Stock Quote or
Examples
Underground Trading - Sat May 10, 2008 04:02PM
This is an update on my speculative long term position p [read more]
Morpheus Trading - Mon May 12, 2008 04:25AM
NOTE: Please click on the charts below to enlarge them if [read more]
Millionaire Now! by Larry Nusbaum - Mon May 12, 2008 04:54AM
MORNING MARKET COMMENTARYfor Monday, May 12, 2008Weak Financ [read more]

PREMIER SPONSORED LINKS

Most Visited Blogs | Most Popular Blogs | Most Recent Blogs | Contact Us | Terms and conditions | Privacy Policy

The columns, articles, message board posts and any other features provided on TheMoneyBlogs.com are provided for personal finance, education and investment information and are not to be construed as investment advice. Under no circumstances does the information in this content represent a recommendation to buy, sell or hold any security. The views and opinions expressed in an article or column are the author's own and not necessarily those of TheMoneyBlogs.com and there is no implied endorsement by TheMoneyBlogs.com of any advice or trading strategy. The analysts and employees or affiliates of TheMoneyBlogs.com may hold positions in the stocks or industries discussed here. Your use of this and all information contained on TheMoneyBlogs.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.

Copyright © 2008 The Connors Group, Inc.